newsfilter
← Latest News
Business Wire·

BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer

Recommendation based on results of three Phase 3 clinical trials demonstrating benefit of tislelizumab as a first- and second-line treatment for patients with NSCLC BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: